MARKET

RDHL

RDHL

Redhill Biopharm
NASDAQ
1.020
-0.010
-0.97%
After Hours: 1.020 0 0.00% 16:04 05/12 EDT
OPEN
1.000
PREV CLOSE
1.030
HIGH
1.020
LOW
0.9700
VOLUME
15.10K
TURNOVER
--
52 WEEK HIGH
3.310
52 WEEK LOW
0.7101
MARKET CAP
5.30M
P/E (TTM)
-0.4454
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RDHL last week (0504-0508)?
Weekly Report · 1d ago
Weekly Report: what happened at RDHL last week (0427-0501)?
Weekly Report · 05/04 10:07
RedHill Biopharma Reports Promising MAP-Killing Data for Next-Generation Crohn’s Candidate RHB-204
TipRanks · 04/30 12:16
RedHill Biopharma’s RHB-204 shows efficacy in Crohn’s Disease
TipRanks · 04/30 11:52
Redhill Biopharma Announces New In Vitro Testing Results Demonstrating RHB-204's Comparability To RHB-104 In Mycobacterium Avium Subspecies Paratuberculosis Killing Efficacy
Benzinga · 04/30 11:12
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
PR Newswire · 04/30 11:00
RedHill Biopharma Reshapes Talicia Franchise and Strengthens Balance Sheet in 2025 Results
TipRanks · 04/27 12:29
Redhill Biopharma FY EPS $0.00, Sales $286.000K Down From $8.043M YoY
Benzinga · 04/27 12:14
More
About RDHL
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Webull offers RedHill Biopharma Ltd (ADR) stock information, including NASDAQ: RDHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDHL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RDHL stock methods without spending real money on the virtual paper trading platform.